C-Control: Efficacy and Safety of Therapy With Rosuvastatin in Statin-Naive and in Statin-Switched Patients

AstraZeneca

Status: Completed

Conditions: Hypercholesteremia

Study type: Observational

Funder types: Industry

Identifiers

NCT00688454

NIS-CCH-CRE-2007/1

Details and patient eligibility

About

The study explores efficacy and safety of the lipid-lowering therapy with CRESTOR in statin-naive patients and in patients with previously unsuccessful statin therapy. This study was designed to investigate the dynamic of the lipid parameters and therapy tolerability during 8-10 weeks treatment with CRESTOR

Enrollment: 3,392 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hypercholesteremia who was never treated with statins before
• Patient with hypercholesteremia who was treated with a statin (other then rosuvastatin) but because of its adverse effects/insufficient action was switched to therapy with CRESTOR

Exclusion criteria

• None

Trial design

3,392 participants in 1 patient group

Pt with hypercholesteremia

Description:

Patients treated with CRESTOR because of hypercholesteremia